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On 13 November, WikiLeaks released a secret draft text of 
the Intellectual Property Chapter of the Trans-Pacific 
Partnership (TPP). The text reveals substantive proposals for 
expanded protection in respect of copyright, patent, trade 
mark and trade secrets law, and intellectual property 
enforcement.
Across this, there is much cause for concern. In particular, 
the IP Chapter poses worrying challenges for patient care, 
access to medicines, and public health across the Pacific 
Rim. As WikiLeaks Editor-in-Chief Julian Assange warned, 
‘[i]f you’re ill now or might one day be ill, the TPP has you in 
its crosshairs’.
With the drafting notes intact in the leaked TPP draft, the 
text reveals a fierce battle amongst the Pacific Rim nations 
over patent law, public health, and the objectives and the 
principles behind the TPP’s IP Chapter.
New Zealand, Canada, Singapore, Chile, Malaysia and 
Vietnam have proposed that the agreement should ‘support 
each Party’s right to protect public health, including by 
facilitating timely access to affordable medicines’. As an 
additional clause, New Zealand, Canada, Singapore, Chile 
and Malaysia have proposed the agreement should 
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recognise that countries can ‘adopt measures necessary to 
protect public health and nutrition’.
The US and Japan opposed such recognition of the 
importance of public health in the agreement’s objectives, 
with Peru, Brunei Darussalam and Mexico withdrawing their 
names from the proposal to include public health in the TPP 
objectives. In contrast, Australia has reserved its position on 
the scope of the objectives — a disappointing stance given 
that Australian leaders have publicly emphasised the 
importance of public health measures, such as access to 
medicines and the plain packaging of tobacco products.
The TPP contains a raft of measures designed to boost the 
position of patent holders in the fields of pharmaceutical 
drugs, medicine and biotechnology.
The US has proposed a broad approach to patent law —
demanding that plants, animals and medical procedures be 
subject to patent protection by Pacific Rim members. This 
could result, particularly for medical procedures, in greater 
patent litigation against doctors, surgeons and medical 
professionals.
In addition, the US has argued for extensions of the patent 
term in respect of pharmaceutical drugs, including 
extensions where there have been regulatory delays —
something which could result in skyrocketing healthcare 
prices. A review of pharmaceutical drug patents in Australia, 
for example, found that patent term extensions were 
exceedingly expensive in Australia.
There has also been concern about the problem of patent 
‘ever greening’ — that the TPP will impose low patent 
standards ‘likely to lead to a proliferation of secondary 
patents being granted … preventing fair competition for long 
periods’. This would be an undesirable outcome, creating 
excessive opportunities for the extension of monopoly 
protections.
The US also argues for patent-registration linkages to 
marketing regimes. There has been significant debate over 
the protection of undisclosed data for regulatory purposes. 
The US has proposed 12 years for data exclusivity for 
biological medical products, though the text on this proposal 
was, unfortunately, not amongst the leaked material. The 
US has also controversially pushed for the cross-border 
seizure of infringing IP in transit. In light of past 
controversies with the seizure of Indian generic drugs, it is 
possible that such text could result in the interdiction of 
medicines in transit.
Given what is at stake, the TPP is a matter of life and death: 
it will affect access to life-saving medicines, drugs and 
treatments in developed and developing countries across the 
Pacific.
It is also very questionable whether the TPP’s IP Chapter 
fully embodies international understandings about the need 
for flexible public health measures, as reflected in the WTO 
through the Doha Declaration on the TRIPS Agreement and 
Public Health 2001 and the Decision of the General Council 
of 30 August 2003.
The US and its allies have proposed measures that would 
raise prices and reduce competition. This includes the 
Obama administration’s revocation of a 2007 agreement 
between the Bush administration and the Democrat-
controlled Congress to give developing countries more 
flexible access to medicines through IP laws. In addition, the 
US has sought to limit the use of compulsory licensing, 
which would provide access to patented inventions in 
respect of medicines.
A group of five countries — Canada, Chile, Malaysia, New 
Zealand and Singapore — have put forward a counter-
proposal to the US demands on medicines. Krista Cox of 
Knowledge Ecology International observed that the counter-
proposal ‘preserves TRIPS flexibilities, and specifically takes 
into account important factors including the public interest, 
levels of development, and the potential for abuse of 
intellectual property rights by the right holders’.
Australia has been passive in the debate over access to 
medicines. Earlier this year, the Coalition party, then in 
opposition, opposed a bill that would have provided for the 
export of essential medicines to developing countries. It will 
be interesting to see what stance the now in-office Coalition 
government will take in the TPP on IP and drug pricing.
As all this suggests, the TPP’s draft IP Chapter confirms 
many of the concerns put forward by public health 
advocates prior to its release. The TPP is a surgical strike 
against public health. The text demands that signatory 
parties amend their laws in a manner that risks the health of 
their citizens and is ethically questionable. Médecins Sans 
Frontières has warned: ‘The leak of the secret text confirms 
that the US government continues to steamroll its trading 
partners in the face of steadfast opposition over terms that 
will severely restrict access to affordable medicines for 
millions of people’.
Obama may struggle, though, to obtain support for the TPP 
from the US Congress. Indeed, 151 House Democrats and 
25 House Republicans have already signalled their 
opposition to granting Obama a fast-track authority for the 
TPP. And, on the 27 November, after much criticism at the 
Salt Lake City talks, the USTR announced that it will put 
forward new revised proposals on intellectual property and 
access to medicines in the TPP. It remains to be seen 
whether such proposals will remain unpalatable to the other 
Pacific Rim nations.
Print
Download PDF
Novartis vs. the 
government of India: 
patents and public…
by Hans Lofgren
Smoke and mirrors in 
trade disputes will 
harm public health by 
Matthew Rimmer
The Trans-Pacific 
Partnership, the 
environment and 
climate… by Matthew 
Rimmer
Alexandra Phelan is an international health and human 
rights lawyer and doctoral candidate specialising in global 
health law at Georgetown University, Washington DC.
Dr Matthew Rimmer is an Australian Research Council Future 
Fellow, an Associate Professor at the ANU College of Law, 
and an Associate Director of the Australian Centre for 
Intellectual Property in Agriculture (ACIPA).
SHARE:
View more posts by Matthew Rimmer, Alexandra Phelan
RELATED POSTS
 + J ] 8
190 8 3
